Renal prostaglandins and kallikrein are considered to play an important role in the control of renin release. Recently, we have shown that aprotinin, a kallikrein inhibitor, inhibits the stimulation of plasma renin activity (PRA) by either furosemide or a low sodium diet. However, the mechanisms of action of kallikrein are unknown. Since kallikrein may stimulate bradykinin and prostaglandin production, the present study examines the relationship of renal kallikrein and renal prostaglandins in the control of renin release. Furosemide and a low sodium diet stimulated PRA, urinary kallikrein excretion and urinary prostaglandin E2 excretion. Aprotinin and indomethacin inhibited both furosemide and low sodium diet stimulation of PRA. When maximum doses of both aprotinin and indomethacin were given, PRA was more strongly suppressed than by indomethacin alone. The stimulation of urinary kallikrein excretion by furosemide and by a low sodium diet was not inhibited by indomethacin.
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10,000U/Kg, had the same effect, and the effects of 5,000U/Kg and 10,000 U/Kg of aprotinin were identical. Fig.4 shows the effects of both separate and combined administration of aprotinin and indomethacin on the furosemide-induced increase in PRA. The results of this study clearly show that both renal kallikrein and prostaglandins play an important role in the control of the renin release elicited by furosemide and by a low sodium diet.
Aprotinin can inhibit both plasma kallikrein and renal kallikrein.28) However, since soy-bean trypsin inhibitor, which inhibits plasma kallikrein, trypsin and chymotrypsin but not renal kallikrein,28) does not affect PRA in sodium depleted conditions, it is clear that plasma kallikrein, trypsin and chymotrypsin do not play an important role in the control of renin release in sodium depleted rats. Rat urinary kallikrein excretion was measured in the present study by the esterase method which was established by Moriya et al.20) They reported that their method was 100 times more sensitive than the hydrozamate-ferric complex method and 10 times more sensitive than chromotropic acid method. They also showed that the data which was obtained by their method are in agreement with bioassay data.
They concluded that their method is useful for the measurement of small amounts of kallikrein in physiological or pathological investigations.
It has also been reported that rat urinary kallikrein measured by esterolytic activity is correlated with radioimmunoassay results.29) The possibility that esterase A plays an important role in the control of renin release can be excluded, since soy-bean trypsin inhibitor inhibits esterase A and does not affect the renin release stimulated by furosemide and by a low sodium diet.17)
Urinary kallikrein excretion and urinary prostaglandin E2 excretion were increased by furosemide treatment and by a low sodium diet.
Since aprotinin inhibited this increment; furosemide and a low sodium diet probably stimulate renin release via kallikrein and prostaglandin production.
However, the lack of efficacy of indomethacin in blocking kallikrein excretion effects suggests that kallikrein and prostaglandin mechanisms are independent. This is supported by the finding that effects of aprotinin and indomethacin against furosemideand low sodium diet-induced PRA increments were additive.
Thus, kallikrein actions are not mediated solely through increased prostaglandin production.
Although the mechanisms of action of kallikrein are not clear, kallikrein may activate inactive renin in the kidney , since it is a proteolytic enzyme and can activate inactive renin in plasma . 
